Cyclo Therapeutics (NASDAQ:CYTH) Shares Up 1.4% – Here’s Why

Cyclo Therapeutics, Inc. (NASDAQ:CYTH)’s stock price shot up 1.4% during trading on Friday . The stock traded as high as $0.85 and last traded at $0.82. 33,205 shares were traded during mid-day trading, a decline of 37% from the average session volume of 52,627 shares. The stock had previously closed at $0.81.

Cyclo Therapeutics Price Performance

The business’s 50-day simple moving average is $0.67 and its two-hundred day simple moving average is $0.81. The stock has a market cap of $23.62 million, a price-to-earnings ratio of -0.91 and a beta of -0.49.

Cyclo Therapeutics Company Profile

Cyclo Therapeutics, Inc, a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease.